Mid Atlantic Retina is an internationally recognized, pre-eminent retina practice in Pennsylvania, New Jersey and Delaware, delivering state-of-the-art, comprehensive patient care for over 40 years. Our practice is dedicated to the diagnosis and treatment of retina, vitreous and macula disorders, with the goal of improving the quality of life of our patients.
All of our doctors are:
Our 19 retina specialists utilize the most advanced therapies and surgical approaches, combined with an unfailing attention to consistency and detail, to provide the best treatment available.
On the Leading Edge of Technology - All of our offices have the latest diagnostic and therapeutic services.
We Keep Our Patients Informed - by providing information on common diseases in print and on our website.
Easily Accessible Offices - Our offices are easy to find, with multiple locations throughout the tri-state area.
The Mid Atlantic Retina doctors, staff and our families are excited to partner with the American Diabetes Association for the Tour de Cure on Saturday, June 2, 2012 at Temple University, Ambler Campus. Every dollar raised through Tour de Cure supports critical diabetes research, information and advocacy. If you are interested in joining us or participating on your own, visit our team page at: http://main.diabetes.org/goto/martourdecure or contact our team captain January Higgins at jhiggins@midatlanticretina.com / 267-433-1106.
_____________________________________________________________________
We are pleased to announce the opening of our newest office in Wilmington, Delaware. Call 1-800-331-6634 for an appointment
_____________________________________________________________________
Genetic testing for age-related macular degeneration is now available at Mid Atlantic Retina. Click here to learn more about how genetic testing may help improve outcomes in patients with this disease.
_____________________________________________________________________
Mid Atlantic Retina is now participating in clinical trials looking at potential new therapies for patients with an advanced form of the dry type of age-related macular degeneration called geographic atrophy. For more information, please contact our Research Department at 215-928-3092.